Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen already has its own antibody technology – known as BiTE – which enables the identification and development of bispecific T cell engager antibodies. ... TNB-585 is a bispecific T cell-engager being evaluated for the treatment of metastatic

Latest news

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.

  • Deal Watch September 2016 Deal Watch September 2016

    In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

  • Deal Watch June 2016 Deal Watch June 2016

    2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell malignancies (preclinical) and other rights. ... licence. 125. EpimAb Biotherapeutics/ Innovent Biologics. Fabs-In-Tandem immunoglobulin platform to develop multiple

  • Deal Watch April 2016 Deal Watch April 2016

    The collaboration provides GSK with a platform technology to develop bispecific antibodies. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...